SGLT2抑制剂对心律失常的长期影响:系统性审查和元分析
Peipei Li1, Weiwei Chen1, Rui Chen2
1Department of Cardiology, Jilin Provincial Cardiovascular Research Institute, China-Japan Union Hospital of Jilin University, Changchun, China.
Frontiers in pharmacology
|July 17, 2025
概括
-葡萄糖共载体2 (SGLT2) 抑制剂显著降低了心房动和心房动的风险. 然而,这些SGLT2抑制剂不会影响心室动脉冲动,心室动或鼻肌梗塞的风险.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- -葡萄糖共载体2 (SGLT2) 抑制剂因其在心力衰竭治疗中的心脏保护作用而得到认可.
- 对于SGLT2抑制剂对各种心律失常症的影响仍然不完全理解.
研究的目的:
- 系统地审查和元分析SGLT2抑制剂对不同类型心律失常的长期影响.
- 评估SGLT2抑制剂在降低心房动,心房动,心室动脉冲动,心室动和鼻肌梗塞的发生率方面的疗效.
主要方法:
- 在主要数据库 (PubMed,Embase,Web of Science,ClinicalTrials.gov) 进行了系统的搜索,截至2024年6月30日.
- 包括随机对照试验 (RCT) 与至少52周的随访.
- 主要结局:心房动/跳动;次要结局:心室动脉短心,心室动,鼻胸. 计算了具有95%信心区间 (CI) 的聚合风险比率 (RRs).
主要成果:
- 分析了39个RCT,其中有107770名参与者.
- 与安慰剂相比,SGLT2抑制剂显著降低了心房动/动的风险 (RR 0.86; 95%CI, 0.77-0.95; P = 0.003).
- 对于心室低心率,心室动或鼻肌梗塞没有观察到显著差异. 对心房动/动的剂量依赖性影响在统计上并不显著.
结论:
- SGLT2 抑制剂在降低心房动和心房的风险方面具有显著的益处.
- 这些药物似乎没有影响心室节律失常或鼻肌梗塞的风险.
- 不同剂量的SGLT2抑制剂对心房动/动的发生率没有显著的影响.
相关概念视频
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
861
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
861
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.8K
Oral Hypoglycemic Agents: Biguanides and Glitazones
306
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
306
Heart Failure Drugs: Inotropic Agents
733
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
733
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.2K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.2K
Dipeptidyl Peptidase 4 Inhibitors
262
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
262


